• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

DAAO and GlyT1 inhibitors in treatment of Alzheimers, OCD, depression, schizophrenia, and more

P

pgoody

Messages
66
Here is an abstract that discusses the current thoughts behind this kind of treatment:

https://www1.wfsbp-congress.org/guest/SciProgramSessionsList?SSN_ID=832

Currently the top two GlyT1 inhibitors available are sarcosine (an endogenous inhibitor) and Bitopertin (which will be marketed come 2015?).

D-amino acid oxidase (DAAO) inhibitors inhibit the breakdown of d-serine (and other D-amino acids). D-serine is an endogenous co-agonist of the NMDA glycine/d-serine site.

A few more links:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905773/ more in depth explanation

https://www1.wfsbp-congress.org/guest/AbstractView?ABSID=11058 for OCD
https://www1.wfsbp-congress.org/guest/AbstractView?ABSID=11023 for depression
https://www1.wfsbp-congress.org/guest/AbstractView?ABSID=11059 sodium benzoate, a potential DAAO inhibiting agent
https://www1.wfsbp-congress.org/guest/AbstractView?ABSID=12051 for Alzheimers

There are likely other DAAO agents being tested, as I have read some material about this dating back at least 5 years. Sodium benzoate was something I just spotted on this particular site.
 
You must log in or register to reply here.